APO Research
Talk to an analyst

APO RESEARCH · REPORT

Neurodegenerative Disease

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Neurodegenerative Disease Market Outlook and Growth Opportunities 2026

19 December 2025202 pages

Choose your research edition.

Industry ResearchNeurodegenerative Disease Industry Research Report 2026134 pages · $2,950 USDIndustry Growth & TrendsGlobal Neurodegenerative Disease Industry Growth and Trends Forecast to 2032113 pages · $3,450 USDMarket StructureGlobal Neurodegenerative Disease Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032193 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Neurodegenerative Disease Market Outlook and Growth Opportunities 2026202 pages · $4,250 USDMarket Analysis & ForecastGlobal Neurodegenerative Disease Market Analysis and Forecast 2026-2032202 pages · $4,950 USD

Market perspective

The global Neurodegenerative Disease market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Neurodegenerative Disease is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Neurodegenerative Disease is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Neurodegenerative Disease is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Neurodegenerative Disease market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Neurodegenerative Disease market include Biogen Idec, Boehringer Ingelheim, Merck Serono, UCB, BORA PHARMACEUTICALS, Dongcheng Biochemicals, Ark Pharmaceutical, GlaxoSmithKline and Haisco Pharmaceutical, among others. In 2025, the top three vendors together accounted for approximately % of global market revenue.

This report provides an overview of the global Neurodegenerative Disease market in terms of revenue and gross margin, analyzing global market trends using historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Neurodegenerative Disease and market revenue by major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Neurodegenerative Disease revenue, market share, and industry ranking for the main companies for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

Across the 2021-2026 period, the analysis compares revenue growth and profitability profiles by company, distinguishing participants with sustained expansion from those with more cyclical performance, and relates these patterns to differences in regional exposure, product portfolios, and application focus in the global Neurodegenerative Disease market.

Neurodegenerative Disease Segment by Company

Biogen Idec

Boehringer Ingelheim

Merck Serono

UCB

BORA PHARMACEUTICALS

Dongcheng Biochemicals

Ark Pharmaceutical

GlaxoSmithKline

Haisco Pharmaceutical

Hisun Pharmaceutical

Huahai Pharmaceutical

Pfizer

Jingxin Pharmaceutical

Kanghong Pharmaceutical

Livzon Pharmaceutical

Luye Pharma

Novartis

Sanofi

TEVA

Neurodegenerative Disease Segment by Type

NMDA

SSRIs

Dopamine Inhibitors

Neurodegenerative Disease Segment by Application

Alzheimer’s Disease

Huntington Disease

Amyotrophic Lateral Sclerosis

Parkinson’s Disease

Neurodegenerative Disease Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Nordic Countries

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Colombia

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global Neurodegenerative Disease status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the Neurodegenerative Disease key companies, revenue, market share, and recent developments.

3. To split the Neurodegenerative Disease breakdown data by regions, type, companies, and application.

4. To analyze the global and key regions Neurodegenerative Disease market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Neurodegenerative Disease significant trends, drivers, influence factors in global and regions.

6. To analyze Neurodegenerative Disease competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Neurodegenerative Disease market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Neurodegenerative Disease and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Neurodegenerative Disease.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Neurodegenerative Disease industry.

Chapter 3: Detailed analysis of Neurodegenerative Disease company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales value of Neurodegenerative Disease in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.

Chapter 7: Sales value of Neurodegenerative Disease in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

Chapter 9: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Neurodegenerative Disease Industry Trends Table 2. Neurodegenerative Disease Industry Drivers Table 3. Neurodegenerative Disease Industry Opportunities and Challenges Table 4. Neurodegenerative Disease Industry Restraints Table 5. Global Neurodegenerative Disease Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Neurodegenerative Disease Revenue Share by Company (2021-2026) Table 7. Global Neurodegenerative Disease Company Ranking, (2024-2026) & (US$ Million) Table 8. Global Neurodegenerative Disease Key Company Manufacturing Base & Headquarters Table 9. Global Neurodegenerative Disease Company, Product Type & Application Table 10. Global Neurodegenerative Disease Company Establishment Date Table 11. Global Company Market Concentration Ratio (CR5 and HHI) Table 12. Global Neurodegenerative Disease by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 13. Mergers & Acquisitions, Expansion Table 14. Significant Companies of NMDA Table 15. Significant Companies of SSRIs Table 16. Significant Companies of Dopamine Inhibitors Table 17. Global Neurodegenerative Disease Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 18. Global Neurodegenerative Disease Sales Value by Type (2021-2026) & (US$ Million) Table 19. Global Neurodegenerative Disease Sales Value by Type (2027-2032) & (US$ Million) Table 20. Global Neurodegenerative Disease Sales Value Share by Type (2021-2026) Table 21. Global Neurodegenerative Disease Sales Value Share by Type (2027-2032) Table 22. Significant Companies of Alzheimer’s Disease Table 23. Significant Companies of Huntington Disease Table 24. Significant Companies of Amyotrophic Lateral Sclerosis Table 25. Significant Companies of Parkinson’s Disease Table 26. Global Neurodegenerative Disease Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 27. Global Neurodegenerative Disease Sales Value by Application (2021-2026) & (US$ Million) Table 28. Global Neurodegenerative Disease Sales Value by Application (2027-2032) & (US$ Million) Table 29. Global Neurodegenerative Disease Sales Value Share by Application (2021-2026) Table 30. Global Neurodegenerative Disease Sales Value Share by Application (2027-2032) Table 31. Global Neurodegenerative Disease Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 32. Global Neurodegenerative Disease Sales Value by Region (2021-2026) & (US$ Million) Table 33. Global Neurodegenerative Disease Sales Value Share by Region (2021-2026) Table 34. Global Neurodegenerative Disease Sales Value by Region (2027-2032) & (US$ Million) Table 35. Global Neurodegenerative Disease Sales Value Share by Region (2027-2032) Table 36. Global Neurodegenerative Disease Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 37. Global Neurodegenerative Disease Sales Value by Country (2021-2026) & (US$ Million) Table 38. Global Neurodegenerative Disease Sales Value Market Share by Country (2021-2026) Table 39. Global Neurodegenerative Disease Sales Value by Country (2027-2032) & (US$ Million) Table 40. Global Neurodegenerative Disease Sales Value Market Share by Country (2027-2032) Table 41. Biogen Idec Company Information Table 42. Biogen Idec Business Overview Table 43. Biogen Idec Neurodegenerative Disease Revenue (US$ Million) and Gross Margin (2021-2026) Table 44. Biogen Idec Neurodegenerative Disease Product Portfolio Table 45. Biogen Idec Recent Development Table 46. Boehringer Ingelheim Company Information Table 47. Boehringer Ingelheim Business Overview Table 48. Boehringer Ingelheim Neurodegenerative Disease Revenue (US$ Million) and Gross Margin (2021-2026) Table 49. Boehringer Ingelheim Neurodegenerative Disease Product Portfolio Table 50. Boehringer Ingelheim Recent Development Table 51. Merck Serono Company Information Table 52. Merck Serono Business Overview Table 53. Merck Serono Neurodegenerative Disease Revenue (US$ Million) and Gross Margin (2021-2026) Table 54. Merck Serono Neurodegenerative Disease Product Portfolio Table 55. Merck Serono Recent Development Table 56. UCB Company Information Table 57. UCB Business Overview Table 58. UCB Neurodegenerative Disease Revenue (US$ Million) and Gross Margin (2021-2026) Table 59. UCB Neurodegenerative Disease Product Portfolio Table 60. UCB Recent Development Table 61. BORA PHARMACEUTICALS Company Information Table 62. BORA PHARMACEUTICALS Business Overview Table 63. BORA PHARMACEUTICALS Neurodegenerative Disease Revenue (US$ Million) and Gross Margin (2021-2026) Table 64. BORA PHARMACEUTICALS Neurodegenerative Disease Product Portfolio Table 65. BORA PHARMACEUTICALS Recent Development Table 66. Dongcheng Biochemicals Company Information Table 67. Dongcheng Biochemicals Business Overview Table 68. Dongcheng Biochemicals Neurodegenerative Disease Revenue (US$ Million) and Gross Margin (2021-2026) Table 69. Dongcheng Biochemicals Neurodegenerative Disease Product Portfolio Table 70. Dongcheng Biochemicals Recent Development Table 71. Ark Pharmaceutical Company Information Table 72. Ark Pharmaceutical Business Overview Table 73. Ark Pharmaceutical Neurodegenerative Disease Revenue (US$ Million) and Gross Margin (2021-2026) Table 74. Ark Pharmaceutical Neurodegenerative Disease Product Portfolio Table 75. Ark Pharmaceutical Recent Development Table 76. GlaxoSmithKline Company Information Table 77. GlaxoSmithKline Business Overview Table 78. GlaxoSmithKline Neurodegenerative Disease Revenue (US$ Million) and Gross Margin (2021-2026) Table 79. GlaxoSmithKline Neurodegenerative Disease Product Portfolio Table 80. GlaxoSmithKline Recent Development Table 81. Haisco Pharmaceutical Company Information Table 82. Haisco Pharmaceutical Business Overview Table 83. Haisco Pharmaceutical Neurodegenerative Disease Revenue (US$ Million) and Gross Margin (2021-2026) Table 84. Haisco Pharmaceutical Neurodegenerative Disease Product Portfolio Table 85. Haisco Pharmaceutical Recent Development Table 86. Hisun Pharmaceutical Company Information Table 87. Hisun Pharmaceutical Business Overview Table 88. Hisun Pharmaceutical Neurodegenerative Disease Revenue (US$ Million) and Gross Margin (2021-2026) Table 89. Hisun Pharmaceutical Neurodegenerative Disease Product Portfolio Table 90. Hisun Pharmaceutical Recent Development Table 91. Huahai Pharmaceutical Company Information Table 92. Huahai Pharmaceutical Business Overview Table 93. Huahai Pharmaceutical Neurodegenerative Disease Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 94. Huahai Pharmaceutical Neurodegenerative Disease Product Portfolio Table 95. Huahai Pharmaceutical Recent Development Table 96. Pfizer Company Information Table 97. Pfizer Business Overview Table 98. Pfizer Neurodegenerative Disease Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 99. Pfizer Neurodegenerative Disease Product Portfolio Table 100. Pfizer Recent Development Table 101. Jingxin Pharmaceutical Company Information Table 102. Jingxin Pharmaceutical Business Overview Table 103. Jingxin Pharmaceutical Neurodegenerative Disease Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 104. Jingxin Pharmaceutical Neurodegenerative Disease Product Portfolio Table 105. Jingxin Pharmaceutical Recent Development Table 106. Kanghong Pharmaceutical Company Information Table 107. Kanghong Pharmaceutical Business Overview Table 108. Kanghong Pharmaceutical Neurodegenerative Disease Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 109. Kanghong Pharmaceutical Neurodegenerative Disease Product Portfolio Table 110. Kanghong Pharmaceutical Recent Development Table 111. Livzon Pharmaceutical Company Information Table 112. Livzon Pharmaceutical Business Overview Table 113. Livzon Pharmaceutical Neurodegenerative Disease Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 114. Livzon Pharmaceutical Neurodegenerative Disease Product Portfolio Table 115. Livzon Pharmaceutical Recent Development Table 116. Luye Pharma Company Information Table 117. Luye Pharma Business Overview Table 118. Luye Pharma Neurodegenerative Disease Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 119. Luye Pharma Neurodegenerative Disease Product Portfolio Table 120. Luye Pharma Recent Development Table 121. Novartis Company Information Table 122. Novartis Business Overview Table 123. Novartis Neurodegenerative Disease Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 124. Novartis Neurodegenerative Disease Product Portfolio Table 125. Novartis Recent Development Table 126. Sanofi Company Information Table 127. Sanofi Business Overview Table 128. Sanofi Neurodegenerative Disease Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 129. Sanofi Neurodegenerative Disease Product Portfolio Table 130. Sanofi Recent Development Table 131. TEVA Company Information Table 132. TEVA Business Overview Table 133. TEVA Neurodegenerative Disease Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 134. TEVA Neurodegenerative Disease Product Portfolio Table 135. TEVA Recent Development Table 136. Research Programs/Design for This Report Table 137. Authors List of This Report Table 138. Secondary Sources Table 139. Primary Sources List of Figures Figure 1. Neurodegenerative Disease Product Image Figure 2. Global Neurodegenerative Disease Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Neurodegenerative Disease Market Size (2021-2032) & (US$ Million) Figure 4. Global Neurodegenerative Disease Company Revenue Ranking in 2025 (US$ Million) Figure 5. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 6. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 7. NMDA Image Figure 8. SSRIs Image Figure 9. Dopamine Inhibitors Image Figure 10. Global Neurodegenerative Disease Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 11. Global Neurodegenerative Disease Sales Value Share 2021 VS 2025 VS 2032 Figure 12. Global Neurodegenerative Disease Sales Value Share by Type (2021-2032) Figure 13. Alzheimer’s Disease Image Figure 14. Huntington Disease Image Figure 15. Amyotrophic Lateral Sclerosis Image Figure 16. Parkinson’s Disease Image Figure 17. Global Neurodegenerative Disease Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 18. Global Neurodegenerative Disease Sales Value Share 2021 VS 2025 VS 2032 Figure 19. Global Neurodegenerative Disease Sales Value Share by Application (2021-2032) Figure 20. Global Neurodegenerative Disease Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 21. Global Neurodegenerative Disease Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 22. North America Neurodegenerative Disease Sales Value (2021-2032) & (US$ Million) Figure 23. North America Neurodegenerative Disease Sales Value Share by Country (%), 2025 VS 2032 Figure 24. Europe Neurodegenerative Disease Sales Value (2021-2032) & (US$ Million) Figure 25. Europe Neurodegenerative Disease Sales Value Share by Country (%), 2025 VS 2032 Figure 26. Asia-Pacific Neurodegenerative Disease Sales Value (2021-2032) & (US$ Million) Figure 27. Asia-Pacific Neurodegenerative Disease Sales Value Share by Country (%), 2025 VS 2032 Figure 28. South America Neurodegenerative Disease Sales Value (2021-2032) & (US$ Million) Figure 29. South America Neurodegenerative Disease Sales Value Share by Country (%), 2025 VS 2032 Figure 30. Middle East & Africa Neurodegenerative Disease Sales Value (2021-2032) & (US$ Million) Figure 31. Middle East & Africa Neurodegenerative Disease Sales Value Share by Country (%), 2025 VS 2032 Figure 32. USA Neurodegenerative Disease Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 33. USA Neurodegenerative Disease Sales Value Share by Type, 2025 VS 2032 & (%) Figure 34. USA Neurodegenerative Disease Sales Value Share by Application, 2025 VS 2032 & (%) Figure 35. Canada Neurodegenerative Disease Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 36. Canada Neurodegenerative Disease Sales Value Share by Type, 2025 VS 2032 & (%) Figure 37. Canada Neurodegenerative Disease Sales Value Share by Application, 2025 VS 2032 & (%) Figure 38. Mexico Neurodegenerative Disease Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 39. Mexico Neurodegenerative Disease Sales Value Share by Type, 2025 VS 2032 & (%) Figure 40. Mexico Neurodegenerative Disease Sales Value Share by Application, 2025 VS 2032 & (%) Figure 41. Germany Neurodegenerative Disease Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 42. Germany Neurodegenerative Disease Sales Value Share by Type, 2025 VS 2032 & (%) Figure 43. Germany Neurodegenerative Disease Sales Value Share by Application, 2025 VS 2032 & (%) Figure 44. France Neurodegenerative Disease Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 45. France Neurodegenerative Disease Sales Value Share by Type, 2025 VS 2032 & (%) Figure 46. France Neurodegenerative Disease Sales Value Share by Application, 2025 VS 2032 & (%) Figure 47. U.K. Neurodegenerative Disease Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 48. U.K. Neurodegenerative Disease Sales Value Share by Type, 2025 VS 2032 & (%) Figure 49. U.K. Neurodegenerative Disease Sales Value Share by Application, 2025 VS 2032 & (%) Figure 50. Italy Neurodegenerative Disease Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 51. Italy Neurodegenerative Disease Sales Value Share by Type, 2025 VS 2032 & (%) Figure 52. Italy Neurodegenerative Disease Sales Value Share by Application, 2025 VS 2032 & (%) Figure 53. Spain Neurodegenerative Disease Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 54. Spain Neurodegenerative Disease Sales Value Share by Type, 2025 VS 2032 & (%) Figure 55. Spain Neurodegenerative Disease Sales Value Share by Application, 2025 VS 2032 & (%) Figure 56. Russia Neurodegenerative Disease Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 57. Russia Neurodegenerative Disease Sales Value Share by Type, 2025 VS 2032 & (%) Figure 58. Russia Neurodegenerative Disease Sales Value Share by Application, 2025 VS 2032 & (%) Figure 59. Netherlands Neurodegenerative Disease Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 60. Netherlands Neurodegenerative Disease Sales Value Share by Type, 2025 VS 2032 & (%) Figure 61. Netherlands Neurodegenerative Disease Sales Value Share by Application, 2025 VS 2032 & (%) Figure 62. Nordic Countries Neurodegenerative Disease Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 63. Nordic Countries Neurodegenerative Disease Sales Value Share by Type, 2025 VS 2032 & (%) Figure 64. Nordic Countries Neurodegenerative Disease Sales Value Share by Application, 2025 VS 2032 & (%) Figure 65. China Neurodegenerative Disease Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 66. China Neurodegenerative Disease Sales Value Share by Type, 2025 VS 2032 & (%) Figure 67. China Neurodegenerative Disease Sales Value Share by Application, 2025 VS 2032 & (%) Figure 68. Japan Neurodegenerative Disease Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 69. Japan Neurodegenerative Disease Sales Value Share by Type, 2025 VS 2032 & (%) Figure 70. Japan Neurodegenerative Disease Sales Value Share by Application, 2025 VS 2032 & (%) Figure 71. South Korea Neurodegenerative Disease Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 72. South Korea Neurodegenerative Disease Sales Value Share by Type, 2025 VS 2032 & (%) Figure 73. South Korea Neurodegenerative Disease Sales Value Share by Application, 2025 VS 2032 & (%) Figure 74. India Neurodegenerative Disease Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 75. India Neurodegenerative Disease Sales Value Share by Type, 2025 VS 2032 & (%) Figure 76. India Neurodegenerative Disease Sales Value Share by Application, 2025 VS 2032 & (%) Figure 77. Australia Neurodegenerative Disease Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 78. Australia Neurodegenerative Disease Sales Value Share by Type, 2025 VS 2032 & (%) Figure 79. Australia Neurodegenerative Disease Sales Value Share by Application, 2025 VS 2032 & (%) Figure 80. Southeast Asia Neurodegenerative Disease Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 81. Southeast Asia Neurodegenerative Disease Sales Value Share by Type, 2025 VS 2032 & (%) Figure 82. Southeast Asia Neurodegenerative Disease Sales Value Share by Application, 2025 VS 2032 & (%) Figure 83. Brazil Neurodegenerative Disease Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 84. Brazil Neurodegenerative Disease Sales Value Share by Type, 2025 VS 2032 & (%) Figure 85. Brazil Neurodegenerative Disease Sales Value Share by Application, 2025 VS 2032 & (%) Figure 86. Argentina Neurodegenerative Disease Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 87. Argentina Neurodegenerative Disease Sales Value Share by Type, 2025 VS 2032 & (%) Figure 88. Argentina Neurodegenerative Disease Sales Value Share by Application, 2025 VS 2032 & (%) Figure 89. Chile Neurodegenerative Disease Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 90. Chile Neurodegenerative Disease Sales Value Share by Type, 2025 VS 2032 & (%) Figure 91. Chile Neurodegenerative Disease Sales Value Share by Application, 2025 VS 2032 & (%) Figure 92. Colombia Neurodegenerative Disease Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 93. Colombia Neurodegenerative Disease Sales Value Share by Type, 2025 VS 2032 & (%) Figure 94. Colombia Neurodegenerative Disease Sales Value Share by Application, 2025 VS 2032 & (%) Figure 95. Peru Neurodegenerative Disease Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 96. Peru Neurodegenerative Disease Sales Value Share by Type, 2025 VS 2032 & (%) Figure 97. Peru Neurodegenerative Disease Sales Value Share by Application, 2025 VS 2032 & (%) Figure 98. Saudi Arabia Neurodegenerative Disease Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 99. Saudi Arabia Neurodegenerative Disease Sales Value Share by Type, 2025 VS 2032 & (%) Figure 100. Saudi Arabia Neurodegenerative Disease Sales Value Share by Application, 2025 VS 2032 & (%) Figure 101. Israel Neurodegenerative Disease Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 102. Israel Neurodegenerative Disease Sales Value Share by Type, 2025 VS 2032 & (%) Figure 103. Israel Neurodegenerative Disease Sales Value Share by Application, 2025 VS 2032 & (%) Figure 104. UAE Neurodegenerative Disease Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 105. UAE Neurodegenerative Disease Sales Value Share by Type, 2025 VS 2032 & (%) Figure 106. UAE Neurodegenerative Disease Sales Value Share by Application, 2025 VS 2032 & (%) Figure 107. Turkey Neurodegenerative Disease Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 108. Turkey Neurodegenerative Disease Sales Value Share by Type, 2025 VS 2032 & (%) Figure 109. Turkey Neurodegenerative Disease Sales Value Share by Application, 2025 VS 2032 & (%) Figure 110. Iran Neurodegenerative Disease Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 111. Iran Neurodegenerative Disease Sales Value Share by Type, 2025 VS 2032 & (%) Figure 112. Iran Neurodegenerative Disease Sales Value Share by Application, 2025 VS 2032 & (%) Figure 113. Egypt Neurodegenerative Disease Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 114. Egypt Neurodegenerative Disease Sales Value Share by Type, 2025 VS 2032 & (%) Figure 115. Egypt Neurodegenerative Disease Sales Value Share by Application, 2025 VS 2032 & (%) Figure 116. Years Considered Figure 117. Research Process Figure 118. Key Executives Interviewed

Scope & coverage.

Types
  • NMDA
  • SSRIs
  • Dopamine Inhibitors
Applications
  • Alzheimer’s Disease
  • Huntington Disease
  • Amyotrophic Lateral Sclerosis
  • Parkinson’s Disease
Companies covered
  • Biogen Idec
  • Boehringer Ingelheim
  • Merck Serono
  • UCB
  • BORA PHARMACEUTICALS
  • Dongcheng Biochemicals
  • Ark Pharmaceutical
  • GlaxoSmithKline
  • Haisco Pharmaceutical
  • Hisun Pharmaceutical
  • Huahai Pharmaceutical
  • Pfizer
  • Jingxin Pharmaceutical
  • Kanghong Pharmaceutical
  • Livzon Pharmaceutical
  • Luye Pharma
  • Novartis
  • Sanofi
  • TEVA

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Neurodegenerative Disease Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Neurodegenerative Disease Market Size (2021-2032)
  4. 1.4 Assumptions and Limitations
  5. 1.5 Study Goals and Objectives
2 Neurodegenerative Disease Market Dynamics
  1. 2.1 Neurodegenerative Disease Industry Trends
  2. 2.2 Neurodegenerative Disease Industry Drivers
  3. 2.3 Neurodegenerative Disease Industry Opportunities and Challenges
  4. 2.4 Neurodegenerative Disease Industry Restraints
3 Neurodegenerative Disease Market by Company
  1. 3.1 Global Neurodegenerative Disease Company Revenue Ranking in 2025
  2. 3.2 Global Neurodegenerative Disease Revenue by Company (2021-2026)
  3. 3.3 Global Neurodegenerative Disease Company Ranking (2024-2026)
  4. 3.4 Global Neurodegenerative Disease Company Manufacturing Base and Headquarters
  5. 3.5 Global Neurodegenerative Disease Company Product Type and Application
  6. 3.6 Global Neurodegenerative Disease Company Establishment Date
  7. 3.7 Market Competitive Analysis
  8. 3.7.1 Global Neurodegenerative Disease Market Concentration Ratio (CR5 and HHI)
  9. 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  10. 3.7.3 2025 Neurodegenerative Disease Tier 1, Tier 2, and Tier 3 Companies
  11. 3.8 Mergers and Acquisitions Expansion
4 Neurodegenerative Disease Market by Type
  1. 4.1 Neurodegenerative Disease Type Introduction
  2. 4.1.1 NMDA
  3. 4.1.2 SSRIs
  4. 4.1.3 Dopamine Inhibitors
  5. 4.2 Global Neurodegenerative Disease Sales Value by Type
  6. 4.2.1 Global Neurodegenerative Disease Sales Value by Type (2021 VS 2025 VS 2032)
  7. 4.2.2 Global Neurodegenerative Disease Sales Value by Type (2021-2032)
  8. 4.2.3 Global Neurodegenerative Disease Sales Value Share by Type (2021-2032)
5 Neurodegenerative Disease Market by Application
  1. 5.1 Neurodegenerative Disease Application Introduction
  2. 5.1.1 Alzheimer’s Disease
  3. 5.1.2 Huntington Disease
  4. 5.1.3 Amyotrophic Lateral Sclerosis
  5. 5.1.4 Parkinson’s Disease
  6. 5.2 Global Neurodegenerative Disease Sales Value by Application
  7. 5.2.1 Global Neurodegenerative Disease Sales Value by Application (2021 VS 2025 VS 2032)
  8. 5.2.2 Global Neurodegenerative Disease Sales Value by Application (2021-2032)
  9. 5.2.3 Global Neurodegenerative Disease Sales Value Share by Application (2021-2032)
6 Neurodegenerative Disease Regional Value Analysis
  1. 6.1 Global Neurodegenerative Disease Sales Value by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Neurodegenerative Disease Sales Value by Region (2021-2032)
  3. 6.2.1 Global Neurodegenerative Disease Sales Value by Region: 2021-2026
  4. 6.2.2 Global Neurodegenerative Disease Sales Value by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Neurodegenerative Disease Sales Value (2021-2032)
  7. 6.3.2 North America Neurodegenerative Disease Sales Value Share by Country, 2025 VS 2032
  8. 6.4 Europe
  9. 6.4.1 Europe Neurodegenerative Disease Sales Value (2021-2032)
  10. 6.4.2 Europe Neurodegenerative Disease Sales Value Share by Country, 2025 VS 2032
  11. 6.5 Asia-Pacific
  12. 6.5.1 Asia-Pacific Neurodegenerative Disease Sales Value (2021-2032)
  13. 6.5.2 Asia-Pacific Neurodegenerative Disease Sales Value Share by Country, 2025 VS 2032
  14. 6.6 South America
  15. 6.6.1 South America Neurodegenerative Disease Sales Value (2021-2032)
  16. 6.6.2 South America Neurodegenerative Disease Sales Value Share by Country, 2025 VS 2032
  17. 6.7 Middle East & Africa
  18. 6.7.1 Middle East & Africa Neurodegenerative Disease Sales Value (2021-2032)
  19. 6.7.2 Middle East & Africa Neurodegenerative Disease Sales Value Share by Country, 2025 VS 2032
7 Neurodegenerative Disease Country-level Value Analysis
  1. 7.1 Global Neurodegenerative Disease Sales Value by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Neurodegenerative Disease Sales Value by Country (2021-2032)
  3. 7.2.1 Global Neurodegenerative Disease Sales Value by Country (2021-2026)
  4. 7.2.2 Global Neurodegenerative Disease Sales Value by Country (2027-2032)
  5. 7.3 USA
  6. 7.3.1 USA Neurodegenerative Disease Sales Value Growth Rate (2021-2032)
  7. 7.3.2 USA Neurodegenerative Disease Sales Value Share by Type, 2025 VS 2032
  8. 7.3.3 USA Neurodegenerative Disease Sales Value Share by Application, 2025 VS 2032
  9. 7.4 Canada
  10. 7.4.1 Canada Neurodegenerative Disease Sales Value Growth Rate (2021-2032)
  11. 7.4.2 Canada Neurodegenerative Disease Sales Value Share by Type, 2025 VS 2032
  12. 7.4.3 Canada Neurodegenerative Disease Sales Value Share by Application, 2025 VS 2032
  13. 7.5 Mexico
  14. 7.5.1 Mexico Neurodegenerative Disease Sales Value Growth Rate (2021-2032)
  15. 7.5.2 Mexico Neurodegenerative Disease Sales Value Share by Type, 2025 VS 2032
  16. 7.5.3 Mexico Neurodegenerative Disease Sales Value Share by Application, 2025 VS 2032
  17. 7.6 Germany
  18. 7.6.1 Germany Neurodegenerative Disease Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Germany Neurodegenerative Disease Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Germany Neurodegenerative Disease Sales Value Share by Application, 2025 VS 2032
  21. 7.7 France
  22. 7.7.1 France Neurodegenerative Disease Sales Value Growth Rate (2021-2032)
  23. 7.7.2 France Neurodegenerative Disease Sales Value Share by Type, 2025 VS 2032
  24. 7.7.3 France Neurodegenerative Disease Sales Value Share by Application, 2025 VS 2032
  25. 7.8 U.K.
  26. 7.8.1 U.K. Neurodegenerative Disease Sales Value Growth Rate (2021-2032)
  27. 7.8.2 U.K. Neurodegenerative Disease Sales Value Share by Type, 2025 VS 2032
  28. 7.8.3 U.K. Neurodegenerative Disease Sales Value Share by Application, 2025 VS 2032
  29. 7.9 Italy
  30. 7.9.1 Italy Neurodegenerative Disease Sales Value Growth Rate (2021-2032)
  31. 7.9.2 Italy Neurodegenerative Disease Sales Value Share by Type, 2025 VS 2032
  32. 7.9.3 Italy Neurodegenerative Disease Sales Value Share by Application, 2025 VS 2032
  33. 7.10 Spain
  34. 7.10.1 Spain Neurodegenerative Disease Sales Value Growth Rate (2021-2032)
  35. 7.10.2 Spain Neurodegenerative Disease Sales Value Share by Type, 2025 VS 2032
  36. 7.10.3 Spain Neurodegenerative Disease Sales Value Share by Application, 2025 VS 2032
  37. 7.11 Russia
  38. 7.11.1 Russia Neurodegenerative Disease Sales Value Growth Rate (2021-2032)
  39. 7.11.2 Russia Neurodegenerative Disease Sales Value Share by Type, 2025 VS 2032
  40. 7.11.3 Russia Neurodegenerative Disease Sales Value Share by Application, 2025 VS 2032
  41. 7.12 Netherlands
  42. 7.12.1 Netherlands Neurodegenerative Disease Sales Value Growth Rate (2021-2032)
  43. 7.12.2 Netherlands Neurodegenerative Disease Sales Value Share by Type, 2025 VS 2032
  44. 7.12.3 Netherlands Neurodegenerative Disease Sales Value Share by Application, 2025 VS 2032
  45. 7.13 Nordic Countries
  46. 7.13.1 Nordic Countries Neurodegenerative Disease Sales Value Growth Rate (2021-2032)
  47. 7.13.2 Nordic Countries Neurodegenerative Disease Sales Value Share by Type, 2025 VS 2032
  48. 7.13.3 Nordic Countries Neurodegenerative Disease Sales Value Share by Application, 2025 VS 2032
  49. 7.14 China
  50. 7.14.1 China Neurodegenerative Disease Sales Value Growth Rate (2021-2032)
  51. 7.14.2 China Neurodegenerative Disease Sales Value Share by Type, 2025 VS 2032
  52. 7.14.3 China Neurodegenerative Disease Sales Value Share by Application, 2025 VS 2032
  53. 7.15 Japan
  54. 7.15.1 Japan Neurodegenerative Disease Sales Value Growth Rate (2021-2032)
  55. 7.15.2 Japan Neurodegenerative Disease Sales Value Share by Type, 2025 VS 2032
  56. 7.15.3 Japan Neurodegenerative Disease Sales Value Share by Application, 2025 VS 2032
  57. 7.16 South Korea
  58. 7.16.1 South Korea Neurodegenerative Disease Sales Value Growth Rate (2021-2032)
  59. 7.16.2 South Korea Neurodegenerative Disease Sales Value Share by Type, 2025 VS 2032
  60. 7.16.3 South Korea Neurodegenerative Disease Sales Value Share by Application, 2025 VS 2032
  61. 7.17 India
  62. 7.17.1 India Neurodegenerative Disease Sales Value Growth Rate (2021-2032)
  63. 7.17.2 India Neurodegenerative Disease Sales Value Share by Type, 2025 VS 2032
  64. 7.17.3 India Neurodegenerative Disease Sales Value Share by Application, 2025 VS 2032
  65. 7.18 Australia
  66. 7.18.1 Australia Neurodegenerative Disease Sales Value Growth Rate (2021-2032)
  67. 7.18.2 Australia Neurodegenerative Disease Sales Value Share by Type, 2025 VS 2032
  68. 7.18.3 Australia Neurodegenerative Disease Sales Value Share by Application, 2025 VS 2032
  69. 7.19 Southeast Asia
  70. 7.19.1 Southeast Asia Neurodegenerative Disease Sales Value Growth Rate (2021-2032)
  71. 7.19.2 Southeast Asia Neurodegenerative Disease Sales Value Share by Type, 2025 VS 2032
  72. 7.19.3 Southeast Asia Neurodegenerative Disease Sales Value Share by Application, 2025 VS 2032
  73. 7.20 Brazil
  74. 7.20.1 Brazil Neurodegenerative Disease Sales Value Growth Rate (2021-2032)
  75. 7.20.2 Brazil Neurodegenerative Disease Sales Value Share by Type, 2025 VS 2032
  76. 7.20.3 Brazil Neurodegenerative Disease Sales Value Share by Application, 2025 VS 2032
  77. 7.21 Argentina
  78. 7.21.1 Argentina Neurodegenerative Disease Sales Value Growth Rate (2021-2032)
  79. 7.21.2 Argentina Neurodegenerative Disease Sales Value Share by Type, 2025 VS 2032
  80. 7.21.3 Argentina Neurodegenerative Disease Sales Value Share by Application, 2025 VS 2032
  81. 7.22 Chile
  82. 7.22.1 Chile Neurodegenerative Disease Sales Value Growth Rate (2021-2032)
  83. 7.22.2 Chile Neurodegenerative Disease Sales Value Share by Type, 2025 VS 2032
  84. 7.22.3 Chile Neurodegenerative Disease Sales Value Share by Application, 2025 VS 2032
  85. 7.23 Colombia
  86. 7.23.1 Colombia Neurodegenerative Disease Sales Value Growth Rate (2021-2032)
  87. 7.23.2 Colombia Neurodegenerative Disease Sales Value Share by Type, 2025 VS 2032
  88. 7.23.3 Colombia Neurodegenerative Disease Sales Value Share by Application, 2025 VS 2032
  89. 7.24 Peru
  90. 7.24.1 Peru Neurodegenerative Disease Sales Value Growth Rate (2021-2032)
  91. 7.24.2 Peru Neurodegenerative Disease Sales Value Share by Type, 2025 VS 2032
  92. 7.24.3 Peru Neurodegenerative Disease Sales Value Share by Application, 2025 VS 2032
  93. 7.25 Saudi Arabia
  94. 7.25.1 Saudi Arabia Neurodegenerative Disease Sales Value Growth Rate (2021-2032)
  95. 7.25.2 Saudi Arabia Neurodegenerative Disease Sales Value Share by Type, 2025 VS 2032
  96. 7.25.3 Saudi Arabia Neurodegenerative Disease Sales Value Share by Application, 2025 VS 2032
  97. 7.26 Israel
  98. 7.26.1 Israel Neurodegenerative Disease Sales Value Growth Rate (2021-2032)
  99. 7.26.2 Israel Neurodegenerative Disease Sales Value Share by Type, 2025 VS 2032
  100. 7.26.3 Israel Neurodegenerative Disease Sales Value Share by Application, 2025 VS 2032
  101. 7.27 UAE
  102. 7.27.1 UAE Neurodegenerative Disease Sales Value Growth Rate (2021-2032)
  103. 7.27.2 UAE Neurodegenerative Disease Sales Value Share by Type, 2025 VS 2032
  104. 7.27.3 UAE Neurodegenerative Disease Sales Value Share by Application, 2025 VS 2032
  105. 7.28 Turkey
  106. 7.28.1 Turkey Neurodegenerative Disease Sales Value Growth Rate (2021-2032)
  107. 7.28.2 Turkey Neurodegenerative Disease Sales Value Share by Type, 2025 VS 2032
  108. 7.28.3 Turkey Neurodegenerative Disease Sales Value Share by Application, 2025 VS 2032
  109. 7.29 Iran
  110. 7.29.1 Iran Neurodegenerative Disease Sales Value Growth Rate (2021-2032)
  111. 7.29.2 Iran Neurodegenerative Disease Sales Value Share by Type, 2025 VS 2032
  112. 7.29.3 Iran Neurodegenerative Disease Sales Value Share by Application, 2025 VS 2032
  113. 7.30 Egypt
  114. 7.30.1 Egypt Neurodegenerative Disease Sales Value Growth Rate (2021-2032)
  115. 7.30.2 Egypt Neurodegenerative Disease Sales Value Share by Type, 2025 VS 2032
  116. 7.30.3 Egypt Neurodegenerative Disease Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Biogen Idec
  2. 8.1.1 Biogen Idec Company Information
  3. 8.1.2 Biogen Idec Business Overview
  4. 8.1.3 Biogen Idec Neurodegenerative Disease Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Biogen Idec Neurodegenerative Disease Product Portfolio
  6. 8.1.5 Biogen Idec Recent Developments
  7. 8.2 Boehringer Ingelheim
  8. 8.2.1 Boehringer Ingelheim Company Information
  9. 8.2.2 Boehringer Ingelheim Business Overview
  10. 8.2.3 Boehringer Ingelheim Neurodegenerative Disease Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Boehringer Ingelheim Neurodegenerative Disease Product Portfolio
  12. 8.2.5 Boehringer Ingelheim Recent Developments
  13. 8.3 Merck Serono
  14. 8.3.1 Merck Serono Company Information
  15. 8.3.2 Merck Serono Business Overview
  16. 8.3.3 Merck Serono Neurodegenerative Disease Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Merck Serono Neurodegenerative Disease Product Portfolio
  18. 8.3.5 Merck Serono Recent Developments
  19. 8.4 UCB
  20. 8.4.1 UCB Company Information
  21. 8.4.2 UCB Business Overview
  22. 8.4.3 UCB Neurodegenerative Disease Revenue and Gross Margin (2021-2026)
  23. 8.4.4 UCB Neurodegenerative Disease Product Portfolio
  24. 8.4.5 UCB Recent Developments
  25. 8.5 BORA PHARMACEUTICALS
  26. 8.5.1 BORA PHARMACEUTICALS Company Information
  27. 8.5.2 BORA PHARMACEUTICALS Business Overview
  28. 8.5.3 BORA PHARMACEUTICALS Neurodegenerative Disease Revenue and Gross Margin (2021-2026)
  29. 8.5.4 BORA PHARMACEUTICALS Neurodegenerative Disease Product Portfolio
  30. 8.5.5 BORA PHARMACEUTICALS Recent Developments
  31. 8.6 Dongcheng Biochemicals
  32. 8.6.1 Dongcheng Biochemicals Company Information
  33. 8.6.2 Dongcheng Biochemicals Business Overview
  34. 8.6.3 Dongcheng Biochemicals Neurodegenerative Disease Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Dongcheng Biochemicals Neurodegenerative Disease Product Portfolio
  36. 8.6.5 Dongcheng Biochemicals Recent Developments
  37. 8.7 Ark Pharmaceutical
  38. 8.7.1 Ark Pharmaceutical Company Information
  39. 8.7.2 Ark Pharmaceutical Business Overview
  40. 8.7.3 Ark Pharmaceutical Neurodegenerative Disease Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Ark Pharmaceutical Neurodegenerative Disease Product Portfolio
  42. 8.7.5 Ark Pharmaceutical Recent Developments
  43. 8.8 GlaxoSmithKline
  44. 8.8.1 GlaxoSmithKline Company Information
  45. 8.8.2 GlaxoSmithKline Business Overview
  46. 8.8.3 GlaxoSmithKline Neurodegenerative Disease Revenue and Gross Margin (2021-2026)
  47. 8.8.4 GlaxoSmithKline Neurodegenerative Disease Product Portfolio
  48. 8.8.5 GlaxoSmithKline Recent Developments
  49. 8.9 Haisco Pharmaceutical
  50. 8.9.1 Haisco Pharmaceutical Company Information
  51. 8.9.2 Haisco Pharmaceutical Business Overview
  52. 8.9.3 Haisco Pharmaceutical Neurodegenerative Disease Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Haisco Pharmaceutical Neurodegenerative Disease Product Portfolio
  54. 8.9.5 Haisco Pharmaceutical Recent Developments
  55. 8.10 Hisun Pharmaceutical
  56. 8.10.1 Hisun Pharmaceutical Company Information
  57. 8.10.2 Hisun Pharmaceutical Business Overview
  58. 8.10.3 Hisun Pharmaceutical Neurodegenerative Disease Revenue and Gross Margin (2021-2026)
  59. 8.10.4 Hisun Pharmaceutical Neurodegenerative Disease Product Portfolio
  60. 8.10.5 Hisun Pharmaceutical Recent Developments
  61. 8.11 Huahai Pharmaceutical
  62. 8.11.1 Huahai Pharmaceutical Company Information
  63. 8.11.2 Huahai Pharmaceutical Business Overview
  64. 8.11.3 Huahai Pharmaceutical Neurodegenerative Disease Revenue and Gross Margin (2021-2026)
  65. 8.11.4 Huahai Pharmaceutical Neurodegenerative Disease Product Portfolio
  66. 8.11.5 Huahai Pharmaceutical Recent Developments
  67. 8.12 Pfizer
  68. 8.12.1 Pfizer Company Information
  69. 8.12.2 Pfizer Business Overview
  70. 8.12.3 Pfizer Neurodegenerative Disease Revenue and Gross Margin (2021-2026)
  71. 8.12.4 Pfizer Neurodegenerative Disease Product Portfolio
  72. 8.12.5 Pfizer Recent Developments
  73. 8.13 Jingxin Pharmaceutical
  74. 8.13.1 Jingxin Pharmaceutical Company Information
  75. 8.13.2 Jingxin Pharmaceutical Business Overview
  76. 8.13.3 Jingxin Pharmaceutical Neurodegenerative Disease Revenue and Gross Margin (2021-2026)
  77. 8.13.4 Jingxin Pharmaceutical Neurodegenerative Disease Product Portfolio
  78. 8.13.5 Jingxin Pharmaceutical Recent Developments
  79. 8.14 Kanghong Pharmaceutical
  80. 8.14.1 Kanghong Pharmaceutical Company Information
  81. 8.14.2 Kanghong Pharmaceutical Business Overview
  82. 8.14.3 Kanghong Pharmaceutical Neurodegenerative Disease Revenue and Gross Margin (2021-2026)
  83. 8.14.4 Kanghong Pharmaceutical Neurodegenerative Disease Product Portfolio
  84. 8.14.5 Kanghong Pharmaceutical Recent Developments
  85. 8.15 Livzon Pharmaceutical
  86. 8.15.1 Livzon Pharmaceutical Company Information
  87. 8.15.2 Livzon Pharmaceutical Business Overview
  88. 8.15.3 Livzon Pharmaceutical Neurodegenerative Disease Revenue and Gross Margin (2021-2026)
  89. 8.15.4 Livzon Pharmaceutical Neurodegenerative Disease Product Portfolio
  90. 8.15.5 Livzon Pharmaceutical Recent Developments
  91. 8.16 Luye Pharma
  92. 8.16.1 Luye Pharma Company Information
  93. 8.16.2 Luye Pharma Business Overview
  94. 8.16.3 Luye Pharma Neurodegenerative Disease Revenue and Gross Margin (2021-2026)
  95. 8.16.4 Luye Pharma Neurodegenerative Disease Product Portfolio
  96. 8.16.5 Luye Pharma Recent Developments
  97. 8.17 Novartis
  98. 8.17.1 Novartis Company Information
  99. 8.17.2 Novartis Business Overview
  100. 8.17.3 Novartis Neurodegenerative Disease Revenue and Gross Margin (2021-2026)
  101. 8.17.4 Novartis Neurodegenerative Disease Product Portfolio
  102. 8.17.5 Novartis Recent Developments
  103. 8.18 Sanofi
  104. 8.18.1 Sanofi Company Information
  105. 8.18.2 Sanofi Business Overview
  106. 8.18.3 Sanofi Neurodegenerative Disease Revenue and Gross Margin (2021-2026)
  107. 8.18.4 Sanofi Neurodegenerative Disease Product Portfolio
  108. 8.18.5 Sanofi Recent Developments
  109. 8.19 TEVA
  110. 8.19.1 TEVA Company Information
  111. 8.19.2 TEVA Business Overview
  112. 8.19.3 TEVA Neurodegenerative Disease Revenue and Gross Margin (2021-2026)
  113. 8.19.4 TEVA Neurodegenerative Disease Product Portfolio
  114. 8.19.5 TEVA Recent Developments
9 Concluding Insights
    10 Appendix
    1. 10.1 Reasons for Doing This Study
    2. 10.2 Research Methodology
    3. 10.3 Research Process
    4. 10.4 Authors List of This Report
    5. 10.5 Data Source
    6. 10.5.1 Secondary Sources
    7. 10.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst